6124 RESULTS
Sort By:
RESEARCH NEWS 2006-09-07 Research News Just as amyloid-β toxicity may be attenuated by proteases such as insulin degrading enzyme and neprilysin, tau toxicity may be circumvented by the highly conserved puromycin-sensitive aminopeptidase (PSA)—at least in fruit flies. Alzforum fi
RESEARCH NEWS 2006-09-03 Research News Activation of the pregnane X steroid receptor (PXR) prevents neurodegeneration in a mouse model of the cholesterol metabolic disorder Niemann-Pick C disease, according to a new study from Daniel Ory and colleagues at Washington University Sc
RESEARCH NEWS 2006-09-01 Research News Last year, four independent research groups reported a linkage between polymorphisms in the complement factor H (CFH) gene to age-related macular degeneration (AMD), the most common cause of blindness in people over 60. One particular SNP, w
RESEARCH NEWS 2006-08-27 Research News In the August 25 Cell, researchers led by Michael Shelanski and Ottavio Arancio at Columbia University, New York, report that the enzyme UchL-1, when smuggled into neurons aboard a viral gene construct, can rescue not only synaptic deficits
RESEARCH NEWS 2006-08-25 Research News Molecules of the immune system may look a bit out of place on neurons, but they are increasingly revealing themselves as important players in the brain. Six years ago, Carla Shatz and colleagues from Harvard Medical School found that class I
RESEARCH NEWS 2006-08-24 Research News In Alzheimer disease and other neurodegenerative disorders, chronic activation of glutamatergic neurons is thought to contribute to excitotoxicity and, eventually, neuronal death. But the brain is not defenseless against this onslaught, and
RESEARCH NEWS 2006-08-21 Research News A new mouse model has achieved a long-sought pathological prize—the production of hyperphosphorylated and aggregated tau proteins in a background of elevated Aβ. The trick to linking Aβ to tau’s tangles, it turns out, is to get rid of nitric
RESEARCH NEWS 2006-08-18 Research News The sticky mouse gets its name from the unkempt appearance of its fur, but the animal has more than a cosmetic flaw. Starting at 6 weeks old, sticky mice develop mild tremors, which progress to ataxia because of Purkinje cell neurodegenerati
RESEARCH NEWS 2006-08-16 Research News Mutation or duplication of the protein coding sequence of the α-synuclein gene (SNCA) can cause autosomal dominant inherited Parkinson disease, but the genetic risk factors for the far more common sporadic form of the disease remain murky. N
RESEARCH NEWS 2006-08-12 Research News Clearly, the best way to avoid Alzheimer disease is not to grow old. But why? While the correlation between age and AD is clear, it’s not so apparent how the passage of time brings on toxic amyloid-β (Aβ) aggregates. Aging and the accumulati
RESEARCH NEWS 2006-08-08 Research News Mounting evidence from mouse models points to soluble amyloid-β (Aβ) oligomers as the cause of early, reversible deficits in synapse function and memory (see ARF related news story and Walsh and Selkoe, 2004). But while preventing early syna
RESEARCH NEWS 2006-08-04 Research News Using data from a longitudinal study of nearly 2000 Finnish adults, researchers have devised a simple scoring scheme to judge if the middle aged are at risk of developing dementia later in life. The study, from Miaa Kivipelto at the Karolins
CONFERENCE COVERAGE 2006-08-02 Conference Coverage The 10th International Conference on Alzheimer’s Disease and Related Disorders, held earlier this month in Madrid, offered its share of data on the intricate ways by which the γ-secretase enzyme complex spews out a slew of different fo
CONFERENCE COVERAGE 2006-08-01 Conference Coverage This concludes our 3-part series. Also see part 1 and part 2 or download PDF. Scientists continue to debate the relative merit of using N-terminal versus mid-section or C-terminal antibodies, and of using antibodies against soluble ver
CONFERENCE COVERAGE 2006-08-01 Conference Coverage This is part 2 of our 3-part series. Also see part 1 and part 3 or download PDF. Whatever the fallout of the AN1792 debacle, it has not stopped commercial or academic interest in immunotherapy. Elan Pharmaceuticals and its partner Wyet
